Compare VENUS REMEDIES with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALEMBIC PHARMA VENUS REMEDIES/
ALEMBIC PHARMA
 
P/E (TTM) x -1.1 15.6 - View Chart
P/BV x 0.1 3.9 2.0% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 VENUS REMEDIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ALEMBIC PHARMA
Mar-19
VENUS REMEDIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs126664 19.0%   
Low Rs61412 14.8%   
Sales per share (Unadj.) Rs301.8208.7 144.6%  
Earnings per share (Unadj.) Rs-24.931.0 -80.2%  
Cash flow per share (Unadj.) Rs2.537.1 6.9%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs293.3144.2 203.4%  
Shares outstanding (eoy) m12.34188.52 6.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.6 12.0%   
Avg P/E ratio x-3.817.4 -21.7%  
P/CF ratio (eoy) x36.714.5 253.4%  
Price / Book Value ratio x0.33.7 8.5%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m1,154101,461 1.1%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3937,467 5.3%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72439,347 9.5%  
Other income Rs m2394 24.0%   
Total revenues Rs m3,74739,441 9.5%   
Gross profit Rs m3958,736 4.5%  
Depreciation Rs m3381,152 29.4%   
Interest Rs m354184 192.4%   
Profit before tax Rs m-2757,493 -3.7%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,568 2.0%   
Profit after tax Rs m-3075,844 -5.3%  
Gross profit margin %10.622.2 47.7%  
Effective tax rate %-11.520.9 -54.9%   
Net profit margin %-8.214.9 -55.5%  
BALANCE SHEET DATA
Current assets Rs m2,63819,577 13.5%   
Current liabilities Rs m2,30514,896 15.5%   
Net working cap to sales %8.911.9 75.2%  
Current ratio x1.11.3 87.1%  
Inventory Days Days13590 150.9%  
Debtors Days Days4645 102.2%  
Net fixed assets Rs m4,87127,097 18.0%   
Share capital Rs m123377 32.7%   
"Free" reserves Rs m3,49626,811 13.0%   
Net worth Rs m3,61927,188 13.3%   
Long term debt Rs m1,3744,993 27.5%   
Total assets Rs m7,50947,778 15.7%  
Interest coverage x0.241.7 0.5%   
Debt to equity ratio x0.40.2 206.8%  
Sales to assets ratio x0.50.8 60.2%   
Return on assets %0.612.6 5.0%  
Return on equity %-8.521.5 -39.5%  
Return on capital %1.623.6 6.7%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m019,453 0.0%   
Fx outflow Rs m5176,065 8.5%   
Net fx Rs m-51713,388 -3.9%   
CASH FLOW
From Operations Rs m5148,120 6.3%  
From Investments Rs m-123-7,556 1.6%  
From Financial Activity Rs m-387590 -65.6%  
Net Cashflow Rs m41,153 0.4%  

Share Holding

Indian Promoters % 32.9 74.1 44.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 2.9 6.2%  
FIIs % 0.6 9.1 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 13.9 477.7%  
Shareholders   20,121 49,328 40.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SHASUN PHARMA  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 15, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS